aka LY3305677 · IBI362
Open any panel for the full data
Mazdutide is a dual glucagon/GLP-1 receptor agonist developed by Eli Lilly in partnership with Innovent Biologics in China. Phase 2 trials have shown promising weight loss results.
Third-party creator videos and discussion, surfaced for research context. Amino Axiom does not endorse creator claims.
Mazdutide: The GLP-1/Glucagon Receptor Agonist Flying Under the Radar | Dr. Dan | Obesity Expert
Endocrinology Update – September 23, 2025: Mazdutide OK, Mounjaro teens, CPAP benefit and More
your GLP-1 results will stall without this one thing 👇 resistance training 💪 not walking not yoga not “staying active” lifting heavy thing
I need you to hear this 👇 if you’ve been told your whole life that you just need more discipline, more willpower, more motivation — that wa
true GLP-1 non-response is actually rare 🧬 clinical data suggests it’s only a small fraction of patients. so if your medication “stopped wo